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We read with interest the commentary by Yoshimura 
et al. in relation to our recently published trial investigating 
whether a novel, rapid biomarker-based rule-out of 
ventilator-associated pneumonia (VAP) could improve 
antibiotic stewardship (1).
Antimicrobial resistance is a growing global crisis and 
strategies that aim to improve antibiotic stewardship are 
urgently needed (2). Critically ill patients are at high-risk 
of developing healthcare-associated infections and receive 
a high burden of antibiotics (3,4). The diagnosis of VAP is 
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challenging as clinical and radiological features are non-
specific, with 30–60% of patients with suspected VAP 
ultimately having infection confirmed (5-8). Respiratory 
sampling techniques can have a significant impact on 
the VAP rate observed, with a diagnostic approach based 
on endotracheal aspirate seeming to provide far higher 
false positive rates than an approach based on invasive 
bronchoscoping sampling (9). Moreover, at least in some 
important studies, a bronchoscopic approach has been 
associated with less antibiotic use, less antimicrobial 
resistance, and no signal of harm (10,11).
Our work aimed to address the overuse of antibiotics 
for VAP through the development of novel diagnostics. 
Our trial followed previous single-centre derivation and 
multi-centre validation studies (12,13). Yoshimura et al. 
highlight three potential areas that might explain the similar 
antibiotic use observed in the two groups we studied (one 
having a biomarker-based recommendation on antibiotic 
use, the other routine care). These centred on the quality 
of bronchoalveolar lavage (BAL), the low proportion of 
patients with low biomarker levels in the intervention 
group, and the low compliance with a recommendation to 
stop antibiotics when biomarkers confidently suggested 
VAP was absent. These will be considered in turn.
The assay failures in our trial, pointed out by Yoshimura 
et al., actually related to use of the diagnostic assay. This 
was due to technical issues as a research assay was adopted 
into hospital laboratories. Although there is considerable 
variation in the use of bronchoscopy for the diagnosis 
of VAP in the UK (14), bronchoscopy is still a common 
procedure in intensive care units. In our study BAL was 
performed to a standard operating procedure, often by 
experienced bronchoscopists. Consistent performance of 
the biomarker-test across our studies suggests to us that 
BAL was performed to a consistently high standard. 
Yoshimura and colleagues are correct in saying that, in 
our intervention group, there were fewer “low biomarker” 
results than anticipated. The trial was powered based on a 
modelled change in the frequency distribution of antibiotic-
free days in the 7 days following BAL (15), and not on the 
diagnostic performance of the biomarker or the expected 
number of patients with a rule-out test. The trial did retain 
adequate statistical power to detect a difference in antibiotic 
use, had there been adequate compliance with biomarker-
guided recommendations. 
While we believe the technical issues discussed above 
did not significantly influence the result of our trial, we 
completely agree with the authors that complex clinical 
and behavioural determinants were responsible for non-
compliance with biomarker-guided recommendations, and 
ultimately for the similar, high use of antibiotics in each 
group. Our trial incorporated a process evaluation that 
captured some of this complexity. The study points to an 
important disconnect between clinicians’ stated intentions 
and their prescribing practice which, in our experience, 
was sufficient to obviate the potential benefits of a good 
diagnostic test. Our study suggests that considerable work 
needs to be done to understand these complex behavioural 
issues and prescribing influences, if diagnostic tests are to 
have a greater chance of influencing outcomes in conditions 
like suspected VAP.  
Yoshimura and colleagues are conducting an important 
trial seeking to optimise antibiotic use through Gram 
stain of respiratory samples. Data suggest that the use of 
endotracheal aspirates (rather than BAL) may actually result 
in more antibiotic use (9). While Gram stain may result in a 
narrower spectrum of antibiotics, it will be very interesting 
to see whether the total number of days of antibiotics can be 
reduced. If there is room to add a process evaluation within 
the time-frame of their trial, our experience suggests it may 
yield valuable insights. We wish the authors every success 
with their trial, we very much hope it can deliver benefits to 
patients with VAP, and we look forward to the results.
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